Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion.

Filip BergquistMats EhrneboVincenzo DonadioAnders JohanssonFredrik LundinPer OdinPer SvenningssonNil DizdarElias Eriksson

Published in: Movement disorders clinical practice (2024)

Although DIZ101 or DIZ102 causes approximately four times higher plasma carbidopa levels than LCIG, patients responded equally well to all treatments. The results do not indicate that high plasma carbidopa levels hamper the motor efficacy of levodopa.

Keyphrases

end stage renal disease
parkinson disease
newly diagnosed
ejection fraction
deep brain stimulation
chronic kidney disease
low dose
prognostic factors
high dose